Back to Search
Start Over
European Commission Approves Merck's KEYTRUDA(r) (pembrolizumab) Plus Padcev(r) (enfortumab vedotin-ejfv)
- Source :
- Plus Company Updates. September 3, 2024
- Publication Year :
- 2024
-
Abstract
- RAHWAY: Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA(r), Merck's anti-PD-1 therapy, in combination with Padcev, an antibody-drug conjugate, [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.810870257